Our website uses cookies which are small bits of data stored as text files on your device. We use these cookies as described in our cookie policy. You can disable or change your cookie settings at any time but parts of our site will not function correctly without them.

IncyteCARES is a program for residents of the United States and Puerto Rico.

Copay card icon

Get enrolled in IncyteCARES!

We offer support for eligible patients during treatment, including a program that could make your copay as little as $0.*

*Terms and conditions apply. Terms of this program may change at any time.

Help With Your Insurance Coverage for Jakafi® (ruxolitinib)

When you have a new prescription or a new insurance plan, navigating the details of what’s covered can be stressful. IncyteCARES can help walk you through these challenges. When eligible patients enroll in IncyteCARES, our team can work with you and your Healthcare Professional’s office to get the answers you need on coverage and costs. We may also be able to help with certain insurance requirements or challenges that sometimes arise—so you can focus on taking care of yourself.

CONFIRMING YOUR COVERAGE FOR JAKAFI

Once we receive your prescription and insurance information, IncyteCARES can contact your insurance company to:

  • Find out if your plan will cover Jakafi and how much you may need to pay out of pocket
  • Determine which specialty pharmacies you can use to fill your Jakafi prescription
  • Identify any special steps your insurer may require, such as a prior authorization coverage will be approved

These steps usually take up to 2 business days. Once we have the information, IncyteCARES will call you to review it. If needed, we can also discuss financial assistance options that may be available to you.

HELP WHEN PRIOR AUTHORIZATION IS REQUIRED

Some insurance plans require a prior authorization before they will approve coverage for certain prescription medicines. This means they require your Healthcare Professional to give them more information about your health condition and why Jakafi has been prescribed before they will approve it for coverage. Some insurance plans call this process precertification, prior approval, or something similar. It can sometimes delay how quickly you can fill your Jakafi prescription.

If your plan requires a prior authorization for Jakafi, IncyteCARES can help by tracking and following up on any additional information your plan asked your Healthcare Professional to provide—so you can find out their decision quickly.

APPEALING YOUR INSURER’S DECISION ON JAKAFI COVERAGE

Sometimes, an insurance company may refuse to cover a patient’s Jakafi treatment. By law, the insurer must notify you in writing within a set amount of time to explain why coverage was denied. You also have the right to appeal the insurance company’s decision and have it reviewed by an independent third party. IncyteCARES can provide information to you and your Healthcare Professional about the appeals process if needed.

TEMPORARY SUPPLY OF MEDICINE FOR ELIGIBLE PATIENTS WHEN COVERAGE IS DELAYED

Eligible patients who have been prescribed Jakafi for an FDA-approved use and who are experiencing an insurance coverage delay may be able to receive a free short-term supply of Jakafi. Specific terms and conditions apply to qualify for this program. Learn more.

INDICATIONS AND USAGE

Jakafi is a prescription medicine used to treat adults with polycythemia vera who have already taken a medicine called hydroxyurea and it did not work well enough or they could not tolerate it.

Jakafi is used to treat adults with certain types of myelofibrosis.

Jakafi is also used to treat adults and children 12 years of age and older with acute graft-versus-host disease (GVHD) who have taken corticosteroids and they did not work well enough.

IMPORTANT SAFETY INFORMATION

JAKAFI CAN CAUSE SERIOUS SIDE EFFECTS, INCLUDING:

Low blood counts: Jakafi® (ruxolitinib) may cause your platelet, red blood cell, or white blood cell counts to be lowered. If you develop bleeding, stop taking Jakafi and call your healthcare provider. Your healthcare provider will perform blood tests to check your blood counts before you start Jakafi and regularly during your treatment. Your healthcare provider may change your dose of Jakafi or stop your treatment based on the results of your blood tests. Tell your healthcare provider right away if you develop or have worsening symptoms such as unusual bleeding, bruising, tiredness, shortness of breath, or a fever.

Infection: You may be at risk for developing a serious infection during treatment with Jakafi. Tell your healthcare provider if you develop any of the following symptoms of infection: chills, nausea, vomiting, aches, weakness, fever, painful skin rash or blisters.

Skin cancers: Some people who take Jakafi have developed certain types of non-melanoma skin cancers. Tell your healthcare provider if you develop any new or changing skin lesions.

Increases in cholesterol: You may have changes in your blood cholesterol levels. Your healthcare provider will do blood tests to check your cholesterol levels during your treatment with Jakafi.

The most common side effects of Jakafi include: for certain types of MF and PV – low platelet or red blood cell counts, bruising, dizziness, headache, and diarrhea; and for acute GVHD – low platelet, red or white blood cell counts, infections, and fluid retention.

These are not all the possible side effects of Jakafi. Ask your pharmacist or healthcare provider for more information. Tell your healthcare provider about any side effect that bothers you or that does not go away.

Before taking Jakafi, tell your healthcare provider about: all the medications, vitamins, and herbal supplements you are taking and all your medical conditions, including if you have an infection, have or had tuberculosis (TB) or have been in close contact with someone who has TB, have or had hepatitis B, have or had liver or kidney problems, are on dialysis, high cholesterol or triglycerides, had skin cancer, or have any other medical condition. Take Jakafi exactly as your healthcare provider tells you. Do not change your dose or stop taking Jakafi without first talking to your healthcare provider.

Women should not take Jakafi while pregnant or planning to become pregnant. Do not breastfeed during treatment with Jakafi and for 2 weeks after the final dose.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

You may also report side effects to Incyte Medical Information at 1-855-463-3463.